The approval is based on BRAVE-AA-PEDS, in which 42% of adolescents receiving baricitinib 4 mg achieved at least 80% scalp hair coverage at week 36 vs 5% with placebo.
|Articles|April 1, 2004
Red urine—a red herring?— in an active 6-year-old
You meet your patient late one evening in the emergency department: a 6-year-old boy comfortably asleep as his mother relates their day's events to you.
Advertisement
Advertisement
Related to this article
The FDA accepted the dersimelagon NDA with priority review for EPP and XLP; a decision on the oral MC1R agonist is expected by February 2027.
Children with atopic dermatitis have higher ADHD risk, particularly with early, severe disease and sleep disturbance, a review found.
Baseline severity and clinical phenotype may help predict response to systemic therapy in children with alopecia areata.
Can you guess the diagnosis?
Can you guess the diagnosis?
Phase 3 data show lebrikizumab improved skin clearance, itch, and quality of life in children with moderate-to-severe atopic dermatitis.
FDA approved obinutuzumab for relapsing or steroid-dependent childhood-onset INS, based on INShore data showing 95.5% vs 73.2% sustained remission.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA approves baricitinib for adolescents with severe alopecia areata
2
FDA approves obinutuzumab to reduce relapse risk in childhood-onset idiopathic nephrotic syndrome
3
FAQ: How should pediatricians hand off teens with diabetes?
4
GLP-1 receptor agonists tied to nutritional deficiencies in children, study finds
5